MTVA - MetaVia Inc. Uzoq muddatli majburiyatlarning kapitalga nisbati
MetaVia Inc Parkinson kasalligi terapiyasi uchun innovatsion dori vositalarini ishlab chiqish orqali daromad keltiradi. GURU.Markets platformasida taqdim etilgan joriy uzoq muddatli qarzdorlikning kapitalga nisbati tendentsiyasi 0.01 darajasini ko'rsatmoqda, bu esa kompaniyaning joriy to'lov qobiliyatini aks ettiradi. O'sish istiqbollari neyropatologiyalar uchun davolash usullarining yetishmasligi bilan belgilanadi, biznesning barqarorligi esa bioetikaga rioya qilish va laboratoriya jarayonlariga ekologik yondashuv bilan mustahkamlanadi.
%3A%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_MTVA_-_MetaVia-Inc_-_Long-Term-Debt-to-Equity-Ratio "MTVA: MetaVia, Inc. Uzoq muddatli qarzning kapitalga nisbati 30.11.2024 - 28.10.2026 | 👁️GURU.Markets👁️")
MetaVia Inc. (MTVA) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi bo'yicha ma'lumotlar:
- balans kapitallashuvi bo'yicha ma'lumotlar:
- qarz va likvidlik bo'yicha ma'lumotlar:
Qarzning kapitalga nisbati MetaVia Inc|MTVA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati MetaVia, Inc.|MTVA - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar MetaVia Inc.|MTVA - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli majburiyatlar miqdori MetaVia
Kompaniyaning jamlanma tahliliyoti:MTVA metaviatx.com
MetaVia Inc (MTVA) faoliyatining ko'lami uzoq muddatli majburiyatlar va kapital o'rtasidagi nisbat dinamikasida aks etgan. Ushbu ko'rsatkich moliyaviy richagning darajasini aniqlash uchun uzoq muddatli qarzlar bilan sof aktivlarni taqqoslaydi. Hisob-kitoblar rivojlanishning ichki resurslarga nisbatan tashqi moliyalashtirishga bog'liqligini baholash imkonini beradi. Ilmiy boshqaruv intizomiga ega bo'lgan biofarmatsevtika kompaniyasi uchun me'yoriy qarz kapitalni boshqarishning samaradorligini tasdiqlaydi. Investorlar ushbu muvozanatni klinik sinovlar sur'atini saqlab qolgan holda, defoltga qarshi himoya chorasi deb talqin qiladilar.
Asosiy raqobatchilar
Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi Biogen Inc|Neurocrine Biosciences Inc - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Regencell Corp RGC|Uzoq muddatli qarzning o'z kapitaliga nisbati AXSM (Axsome Therapeutics)|acadia-pharm.com - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Xenon (XENE)|VKTX: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati SUPN|CPRX (Catalyst Corp) - Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati DNLI|Uzoq muddatli qarzning o'z kapitaliga nisbati harmonybiosciences.com|Biohaven - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Amylyx Pharmaceuticals Inc AMLX|Uzoq muddatli qarzning o'z kapitaliga nisbati Trevi Pharma (TRVI)|Uzoq muddatli kreditlarning kapitalga nisbati Praxis Corp PRAX|Anavex Life Sciences - Uzoq muddatli qarzning kapitalga nisbati|ceribell.com (CBLL) - Uzoq muddatli qarzning kapitalga nisbati|Prothena Corp (PRTA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Alector (ALEC) - Uzoq muddatli qarzning o'z kapitaliga nisbati|ANNX: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Omeros Corp.|Uzoq muddatli qarzning kapitalga nisbati NGNE|Uzoq muddatli qarzning kapitalga nisbati acimmune.com ACIU|Uzoq muddatli qarzning o'z kapitaliga nisbati Voyager Therapeutics, Inc.|Uzoq muddatli qarzning kapitalga koeffitsiyenti Neumora NMRA|Uzoq muddatli qarzning kapitalga nisbati SCLX (Scilex Holding Co.)|TVGN: Uzoq muddatli qarzdorlikning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati alphacognition.com|cogrx.com (CGTX) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Uzoq muddatli qarzning kapitalga nisbati IKT|Uzoq muddatli qarzning o'z kapitaliga nisbati SAVA|Uzoq muddatli qarzning o'z kapitaliga nisbati ASRT (Assertio Holdings, Inc.)|Uzoq muddatli qarzning o'z kapitaliga nisbati coyatherapeutics.com COYA|Uzoq muddatli qarzning o'z kapitaliga nisbati Vistagen (VTGN)|OVID - Uzoq muddatli kreditlarning kapitalga nisbati|ABOS - Uzoq muddatli qarzning o'z kapitaliga nisbati|CRVO - Uzoq muddatli qarzning o'z kapitaliga nisbati|ATHE: Uzoq muddatli qarzning kapitalga nisbati|CLNN (Clene) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati PepGen Inc (PEPG)|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi jupiterneurosciences.com|Relmada Therapeutics, Inc. - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Annovis Bio Inc ANVS|Uzoq muddatli qarzning o'z kapitaliga nisbati GRCE (Grace Therapeutics)|Firefly Neuro - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati ANEW Medical, Inc. (KLTO)|NRSN: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati RVPH|NRXS (NeurAxis Inc.) - Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati HSDT|Uzoq muddatli qarzning o'z kapitaliga nisbati Passage Bio Corp|Neuphoria Therapeutics Inc. - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati minervaneurosciences.com NERV|Uzoq muddatli qarzning o'z kapitaliga nisbati Athira Pharma (ATHA)|Uzoq muddatli kreditlarning kapitalga nisbati Addex Therapeutics Ltd. ADXN|Alzamend - Uzoq muddatli qarzning kapitalga nisbati|Cyclerion Therapeutics (CYCN) - Uzoq muddatli qarzning kapitalga nisbati|protagenic.com (PTIX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Pasithea Therapeutics Corp. (KTTA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|CRGT: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Avenue Therapeutics Inc.|Uzoq muddatli qarzning kapitalga nisbati BCLI|Uzoq muddatli qarzning kapitalga nisbati Cara Therapeutics Inc CARA|Uzoq muddatli qarzning o'z kapitaliga nisbati Chromocell Therapeutics|Uzoq muddatli qarzning kapitalga koeffitsiyenti Eliem Therapeutics, Inc. ELYM|Uzoq muddatli qarzning kapitalga nisbati ITCI (Intra-Cellular)|LBPH: Uzoq muddatli qarzdorlikning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Marinus|NKGen Biotech Corp (NKGN) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Uzoq muddatli qarzning kapitalga nisbati NRBO|Uzoq muddatli qarzning o'z kapitaliga nisbati SAGE|Uzoq muddatli qarzning o'z kapitaliga nisbati SNPX (Synaptogenix)|Uzoq muddatli qarzning o'z kapitaliga nisbati Trevena Inc. TRVN|Uzoq muddatli qarzning o'z kapitaliga nisbati Vigil Neuroscience, Inc. (VIGL)|WENA - Uzoq muddatli kreditlarning kapitalga nisbati|CERE - Uzoq muddatli qarzning o'z kapitaliga nisbati